7.0(top 5%)
impact factor
759(top 20%)
papers
11.5K(top 20%)
citations
50(top 10%)
h-index
7.3(top 5%)
extended IF
1.0K
all documents
13.1K
doc citations
68(top 20%)
g-index

Top Articles

#TitleJournalYearCitations
1Epidemiology and Prevention of Prostate CancerEuropean Urology Oncology2021246
2Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trialEuropean Urology Oncology2020187
3A Systematic Review on the Role of Imaging in Early Recurrent Prostate CancerEuropean Urology Oncology2019144
4Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand TherapyEuropean Urology Oncology2019139
5First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisEuropean Urology Oncology2021113
6Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studiesEuropean Urology Oncology2019110
7Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission TomographyEuropean Urology Oncology2018108
8Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical TrialEuropean Urology Oncology2018106
9Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Oncology2021104
10Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisEuropean Urology Oncology2020103
11Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United StatesEuropean Urology Oncology2019100
12What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic ReviewEuropean Urology Oncology201996
13Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical TrialEuropean Urology Oncology202190
14Role of Active Surveillance for Localized Small Renal MassesEuropean Urology Oncology201889
15Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature ReviewEuropean Urology Oncology202088
16Epidemiology, Screening, and Prevention of Bladder CancerEuropean Urology Oncology202288
17Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical ProstatectomyEuropean Urology Oncology202182
18Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate CancerEuropean Urology Oncology201880
19Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic ReviewEuropean Urology Oncology201980
20Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7–10 Prostate Cancer in Biopsy-naïve MenEuropean Urology Oncology201979
21Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic ReviewEuropean Urology Oncology201979
22Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk CalculatorsEuropean Urology Oncology202078
23Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder CancerEuropean Urology Oncology201871
24The Metabolic Landscape of Prostate CancerEuropean Urology Oncology201971
25Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment ChoicesEuropean Urology Oncology202070
26A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer PatientsEuropean Urology Oncology202070
27First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysisEuropean Urology Oncology201968
28Management of Sporadic Renal Angiomyolipomas: A Systematic Review of Available Evidence to Guide Recommendations from the European Association of Urology Renal Cell Carcinoma Guidelines PanelEuropean Urology Oncology202068
29Concordance Between Biopsy and Radical Prostatectomy Pathology in the Era of Targeted Biopsy: A Systematic Review and Meta-analysisEuropean Urology Oncology202068
30Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate CancerEuropean Urology Oncology201967
31A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE)European Urology Oncology202166
32When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going TrialsEuropean Urology Oncology202066
33Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Meta-analysis of Oncologic, Perioperative, and Complication-related outcomesEuropean Urology Oncology201965
34The Importance of Hospital and Surgeon Volume as Major Determinants of Morbidity and Mortality After Radical Cystectomy for Bladder Cancer: A Systematic Review and Recommendations by the European Association of Urology Muscle-invasive and Metastatic Bladder Cancer Guideline PanelEuropean Urology Oncology202065
35Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysisEuropean Urology Oncology202165
36Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO TrialEuropean Urology Oncology201864
37Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive ReviewEuropean Urology Oncology201964
38Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell CarcinomaEuropean Urology Oncology202064
39Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)European Urology Oncology202163
40Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the BladderEuropean Urology Oncology202063
41A European Model for an Organised Risk-stratified Early Detection Programme for Prostate CancerEuropean Urology Oncology202163
42Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective CohortEuropean Urology Oncology202061
43COVID-19 and Bacillus Calmette-Guérin: What is the Link?European Urology Oncology202061
44Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerEuropean Urology Oncology202161
45Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate CancerEuropean Urology Oncology201860
46Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USAEuropean Urology Oncology201860
47Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal MetastasesEuropean Urology Oncology201860
48Staging the Host: Personalizing Risk Assessment for Radical Cystectomy PatientsEuropean Urology Oncology201857
49Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerEuropean Urology Oncology202057
50Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference StandardEuropean Urology Oncology202257